aTyr Pharma Completes Enrollment for Landmark Pulmonary Sarcoidosis Study

aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical-stage biotechnology company, announced the completion of enrollment in its global pivotal Phase 3 EFZO-FIT™ study. The study targets patients with pulmonary sarcoidosis, a significant form of interstitial lung disease (ILD) with limited treatment options. ILD includes over 200 types of rare lung diseases characterized by varying degrees of inflammation and fibrosis. Patients with these conditions often face high morbidity and mortality, and there are currently no disease-modifying therapies available; existing treatments have significant toxicities. aTyr Pharma recently announced a Nasdaq stock ticker symbol change from “LIFE” to “ATYR”. Company shares rose 8% premarket on the news.

Highlights:

• The EFZO-FIT™ study enrolled 268 patients at 85 centers across 9 countries, exceeding the target enrollment.
• This is the largest interventional study ever conducted in pulmonary sarcoidosis
• Topline data from the study are anticipated in the third quarter of 2025.
• Efzofitimod is a tRNA synthetase-derived therapy that modulates activated myeloid cells through neuropilin-2, aiming to resolve inflammation without immune suppression and potentially prevent fibrosis progression.

About aTyr

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.